The German packaging specialist Gerresheimer finds itself in a severe corporate storm, characterized by a delayed annual report, dual regulatory probes, and potential asset impairments nearing a quarter-billion euros. The company’s share price, trading just above its 52-week low, has plummeted approximately 78% from its peak in March 2025.
Regulatory Probes and a Cascade of Delays
At the heart of the turmoil are accounting irregularities. Initial indications suggested revenue from certain customer contracts was recognized prematurely, before being economically realized. This prompted Germany’s financial regulator, BaFin, to commence an investigation in September 2025, which has since been significantly expanded in scope.
BaFin is now scrutinizing not only the 2023/24 financial report but also the period from December 2024 through May 2025. The probe focuses on potentially misstated lease liabilities of €65.5 million and capitalized development costs of €29.4 million.
Simultaneously, a separate special audit by an external firm is analyzing business transactions from 2024 and 2025. The delay in concluding this audit has directly impacted the company’s reporting calendar. Gerresheimer has been forced to postpone the certified group financial statements for 2025, which were initially due by the end of March. Publication is now scheduled for June 2026.
This postponement has triggered a chain reaction of further disruptions. The Q1 2026 quarterly report, originally slated for April 16, and the Annual General Meeting set for June 3 have both been indefinitely deferred.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Operational Fallout and Financial Strain
The operational consequences are substantial. The company anticipates asset impairments between €220 million and €240 million, primarily related to its Swiss subsidiary Sensile Medical and a facility in Chicago. Gerresheimer has acknowledged that its adjusted EBITDA margin for 2025 will miss targets, and a loss per share is a distinct possibility.
In response to the liquidity and covenant pressures, management has initiated talks with its lenders to renegotiate deadlines for submitting the audited financials as stipulated in its financing agreements. To shore up its balance sheet, the firm plans to divest its high-margin US subsidiary Centor—a move expected to provide short-term liquidity but at the cost of weakening the group’s future earnings power.
Market Consequences and Investor Sentiment
The ongoing crisis has severe implications for Gerresheimer’s market standing. The company expects that breaching the Deutsche Börse’s transparency requirements will lead to its exclusion from the SDAX index. Such a delisting would compel index-tracking funds to sell their holdings, creating additional downward pressure on the stock.
Some investors are already betting on further decline. One hedge fund increased its short position on March 11, 2026, from 0.47% to 0.62% of the company’s share capital.
All eyes are now on the certified financial statements expected in June 2026. This report will serve as the definitive test, revealing the full extent of the accounting issues and whether the crucial negotiations with creditors have yielded a sustainable path forward for the embattled company.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from March 16 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 16.
Gerresheimer: Buy or sell? Read more here...
